ArticleCancer2025
Assessing the impact of multidisciplinary team gynecological oncology care in Botswana: A potential model for low- and middle-income countries.
Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adherence to Survivorship Care Visits in Patients With Cervical Cancer in Botswana.JCO global oncology · 2026Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundIn Botswana, a multidisciplinary team (MDT) clinic was established in 2015 to streamline care for all patients with gynecological malignancies including cervical cancer, Botswana's leading cause of cancer mortality.
methodsPatients presenting at the MDT clinic in Gaborone, Botswana, were prospectively enrolled. Temporal trends in stage and treatment distributions were assessed using the Cochran-Armitage χ
resultsBetween 2015 and 2023, 2345 patients were enrolled. Mean age was 52.0 years (SD 13.1 years) and 62.9% (n = 1474) were living with HIV. Annual volume increased 4-fold by 2023. Most patients had cervical cancer (74.3%), followed by vulvar (11.9%), endometrial (8.8%), ovarian (3.6%), and vaginal (1.3%) cancers. Stage distribution was: Stage I 19.2%, Stage II 23.9%, Stage III 31.3%, and Stage IV 9.4%. Trends toward increased diagnosis of Stage I disease (p < .0018) and decreased diagnosis of Stage II disease (p = .002) were observed in cervical cancer patients over the years of MDT consultation. Two-year overall survival for patients with cervical cancer treated between 2015 and 2019 was 67.1% and increased to 75.2% between 2020 and 2024 (p = .002), potentially driven by increased survival of those with Stage II disease (75.7% vs. 84.8%, p = .025). This coincided with an increase in patients with cervical cancer receiving primary surgery (p < .001) and a decrease in those receiving radiotherapy with concurrent chemotherapy (p < .001) and radiotherapy alone (p < .001). DISCUSSION: Gynecological cancer outcomes after MDT clinic establishment significantly improved over time. Although ongoing efforts to optimize care are still needed, the success of the MDT clinic in Botswana can serve as a model for coordinated multidisciplinary care in other low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.